Terms: = Ovarian cancer AND MECOM, MDS1-EVI1, EVI1, 2122, ENSG00000085276, Q03112, PRDM3 AND Treatment
8 results:
1. Ultrasonographic features associated with previous torsion and the impact of surgery in managing neonatal ovarian cysts: a 20-year single-centre retrospective study.
Tyraskis A; Davidson J; Billington J; Blackburn S; Curry J; Mullassery D; Giuliani S; Eaton S; Cross K; De Coppi P
Pediatr Surg Int; 2023 Apr; 39(1):185. PubMed ID: 37095416
[TBL] [Abstract] [Full Text] [Related]
2. PBK, targeted by evi1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
[TBL] [Abstract] [Full Text] [Related]
3. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract] [Full Text] [Related]
4. SUMO1 negatively regulates the transcriptional activity of evi1 and significantly increases its co-localization with evi1 after treatment with arsenic trioxide.
Singh S; Pradhan AK; Chakraborty S
Biochim Biophys Acta; 2013 Oct; 1833(10):2357-68. PubMed ID: 23770046
[TBL] [Abstract] [Full Text] [Related]
5. Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells.
Smith DM; Patel S; Raffoul F; Haller E; Mills GB; Nanjundan M
Cell Death Differ; 2010 Dec; 17(12):1867-81. PubMed ID: 20508647
[TBL] [Abstract] [Full Text] [Related]
6. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.
Nagaraja AK; Creighton CJ; Yu Z; Zhu H; Gunaratne PH; Reid JG; Olokpa E; Itamochi H; Ueno NT; Hawkins SM; Anderson ML; Matzuk MM
Mol Endocrinol; 2010 Feb; 24(2):447-63. PubMed ID: 20081105
[TBL] [Abstract] [Full Text] [Related]
7. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.
Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
BMC Cancer; 2009 Oct; 9():368. PubMed ID: 19835627
[TBL] [Abstract] [Full Text] [Related]
8. Targeted degradation of the AML1/MDS1/evi1 oncoprotein by arsenic trioxide.
Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
[TBL] [Abstract] [Full Text] [Related]
